The Role of Belantamab Mafodotin and Its Impact on Future Treatment Options

Expert oncologists discuss Belantamab mafodotin, its recent withdrawal from the U.S. market, and the clinical implications of the DREAMM trials for patients with R/R multiple myeloma.

Related Videos
Experts on multiple myeloma
Experts on multiple myeloma
Experts on RCC
Experts on RCC
Experts on multiple myeloma
Experts on multiple myeloma
Related Content